Scandinavian ChemoTech is increasing the pace through a credit of mSEK 10
Today, the Company signed an agreement that enables an increased pace for implementation of the new strategy through loans from two lenders of a maximum of mSEK 10.
The agreement strengthens the Company's finances and creates opportunities to begin and complete the strategy that the company developed during the year.
This new credit gives Scandinavian ChemoTech more scope to reach new milestones.
The loan is raised on market terms.
“That, in today's situation, be given the opportunity to secure a little more room for growth feels reassuring. It is important that we as a company now can use the successes we had during the year and increase the conditions for delivering more revenue streams. "- says Mohan Frick, CEO
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-12-2021 20:30 CET.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: email@example.com
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.